ERBB2 and breast carcinoma: Today’s oncologist would also be able to treat this woman with lapatinib, a small molecule that reversibly inhibits HER1 and HER2, and has been used in women with HER2-positive advanced breast cancer that has progressed after treatment with conventional chemotherapy and trastuzumab [16].